Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Steven Busschots"'
Publikováno v:
MethodsX, Vol 2, Iss C, Pp 8-13 (2015)
Many protocols used for measuring the growth of adherent monolayer cells in vitro are invasive, destructive and do not allow for the continued, undisturbed growth of cells within flasks. Protocols often use indirect methods for measuring proliferatio
Externí odkaz:
https://doaj.org/article/7bf835e83765450397fc15f47d05c8d3
Autor:
Aashna, Patel, Roshni, Kalachand, Steven, Busschots, Ben, Doherty, Evangelos, Kapros, Denise, Lawlor, Neville, Hall, Britta K, Stordal
Publikováno v:
Cochrane Database of Systematic Reviews. 2022
Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ova
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aba288b85bf19853165e991b9656d14e
https://doi.org/10.1002/14651858.cd008766.pub3
https://doi.org/10.1002/14651858.cd008766.pub3
Publikováno v:
Experimental Cell Research. 336:1-14
A major risk factor for ovarian cancer is germline mutations of BRCA1/2. It has been found that (80%) of cellular models with acquired platinum or taxane resistance display an inverse resistance relationship, that is collateral sensitivity to the oth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::009259bd4f585dfba2d5608b67fe9bca
https://doi.org/10.1016/j.yexcr.2014.12.001
https://doi.org/10.1016/j.yexcr.2014.12.001
Publikováno v:
MethodsX
MethodsX, Vol 2, Iss C, Pp 8-13 (2015)
MethodsX, Vol 2, Iss C, Pp 8-13 (2015)
Graphical Abstract
Many protocols used for measuring the growth of adherent monolayer cells in vitro are invasive, destructive and do not allow for the continued, undisturbed growth of cells within flasks. Protocols often use indirect methods fo
Many protocols used for measuring the growth of adherent monolayer cells in vitro are invasive, destructive and do not allow for the continued, undisturbed growth of cells within flasks. Protocols often use indirect methods fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::633cd0df1b51724d878b124b50e5ef33
https://doi.org/10.1016/j.mex.2014.11.002
https://doi.org/10.1016/j.mex.2014.11.002
Autor:
John J. O'Leary, Kirsten Timms, Jennifer Potter, Danielle Gallagher, Yang Li, Mattia Cremona, Mickaël Renaud, Britta K. Stordal, Jie Li, Deborah Williams, Thanh Tran, Gordon B. Mills, Ozlem Aslan, Steven Busschots, Greg Korpanty, Mark S. Carey, Angela M. Farrelly, Bryan T. Hennessy, Julien Thery
Publikováno v:
Molecular Oncology. 7:567-579
Mutations in BRCA1/2 increase the risk of developing breast and ovarian cancer. Germline BRCA1/2 mutations occur in 8.6-13.7% of unselected epithelial ovarian cancers, somatic mutations are also frequent. BRCA1/2 mutated or dysfunctional cells may be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a607839adbd386febb613f58b19dee
https://doi.org/10.1016/j.molonc.2012.12.007
https://doi.org/10.1016/j.molonc.2012.12.007
Autor:
Martin Clynes, Martina McDermott, Britta K. Stordal, Laura Breen, Norma O'Donovan, Steven Busschots, John Crown, Alex J Eustace
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Frontiers in Oncology
Frontiers in Oncology
The development of a drug-resistant cell line can take from 3 to 18 months. However, little is published on the methodology of this development process. This article will discuss key decisions to be made prior to starting resistant cell line developm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56804e71b421ea2432153b8b56a8b9fe
http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00040/full
http://journal.frontiersin.org/Journal/10.3389/fonc.2014.00040/full
Autor:
Bryan T. Hennessy, Denise Lawlor, Patricia Martin, Britta K. Stordal, Steven Busschots, Julien Thery, John J. O'Leary
Publikováno v:
Journal of pharmaceutical sciences. 103(6)
The cytotoxicity of PARP inhibitors olaparib, veliparib, and CEP-8983 were investigated in two P-glycoprotein (P-gp) overexpressing drug-resistant cell models (IGROVCDDP and KB-8-5-11). IGROVCDDP and KB-8-5-11 were both resistant to olaparib and resi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cdd1a9fa68cb26155ccd21c3f6d6907
https://pubmed.ncbi.nlm.nih.gov/24700236
https://pubmed.ncbi.nlm.nih.gov/24700236